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Abstract
Background: Despite considerable efforts, a suitable vaccine against Onchocerca volvulus infection has remained elusive.
Herein, we report on the use of molecular tools to identify and characterize O. volvulus antigens that are possibly associated
with the development of concomitant immunity in onchocerciasis.
Methodology/Principal Findings: Third-stage larvae (L3) and molting L3 (mL3) O. volvulus stage-specific cDNA libraries
were screened with a pool of sera from chronically infected patients who had likely developed such immunity. The 87
immunoreactive clones isolated were grouped into 20 distinct proteins of which 12 had already been cloned and/or
characterized before and 4 had been proven to be protective in a small O. volvulus animal model. One of these,
onchocystatin (Ov-CPI-2), a previously characterized O. volvulus cysteine proteinase inhibitor was, overall, the most
abundant clone recognized by the immune sera in both the L3 and mL3 cDNA libraries. To further characterize its
association with protective immunity, we measured the IgG subclass and IgE class specific responses to the antigen in
putatively immune (PI) and infected (INF) individuals living in a hyperendemic area in Cameroon. It appeared that both
groups had similar IgG3 and IgE responses to the antigen, but the INF had significantly higher IgG1 and IgG4 responses than
the PI individuals (p,0.05). In the INF group, the IgG3 levels increased significantly with the age of the infected individuals
(r=0.241; p,0.01). The IgG1 responses in the INF were high regardless of age. Notably, culturing L3 in vitro in the presence
of anti-Ov-CPI-2 monospecific human antibodies and naı ¨ve neutrophils resulted in almost complete inhibition of molting of
L3 to L4 and to cytotoxicity to the larvae.
Conclusions/Significance: These results add to the knowledge of protective immunity in onchocerciasis and support the
possible involvement of anti-Ov-CPI-2 IgG1 and/or IgG3 cytophilic antibodies in the development of protective immunity in
the PI and the INF. The results further support the consideration of Ov-CPI-2 as a leading target for an anti-L3 vaccine.
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Introduction
Human onchocerciasis (river blindness) is a highly debilitating
and blinding disease caused by the nematode, Onchocerca volvulus.
Over 37 million people in endemic countries of tropical Africa,
Latin America and the Arabian Peninsula are infected [1].
Currently, there is no cure for the disease and a vaccine is yet to be
developed. Importantly, protective immunity against O. volvulus
larvae has now been definitively demonstrated in humans, cattle
and mice, thereby proving the conceptual underpinnings that a
vaccine can be produced against this infection [2]. Both clinical
and epidemiological data support also the concept that acquired
immunity against O. volvulus infection occurs in infected humans
and that this immunity increases with age. In chronically infected
(INF) individuals in highly endemic settings, the skin microfilariae
(mf) density tends to increase with age until the ages of 20 to 40 in
most studies, suggesting that older individuals do develop a means
of limiting further infections [3]. A similar trend was also observed
for adult worms where in areas of high transmission, the number
of palpable nodules reached an average of 3–5 over time and then
leveled-off [4]. While it is conceivable that products from the
existing infections may as well prevent super infections from
getting established, the conglomeration of at times a few adult
worms in one nodule is rather at odds with this perception. The
leveling off of patent infections with age is consistent with the
concept of concomitant immunity [5,6], which is characterized by
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infective-stage larvae (L3), while the established adult worms and
microfilariae are left almost unaffected.
Further evidence for the development of concomitant immunity
in filarial infections comes from studies of lymphatic filariasis,
where it was associated with parasite stage-specific immune
responses. Levels of antibodies against Wuchereria bancrofti infective
stage larvae (L3) were found to increase with duration of exposure
[7], and there were differences in the class and subclass antibody
responses to adult versus larval antigens of Brugia malayi [8]. More
recently, the concept of concomitant immunity was further verified
experimentally using the Acanthocheilonema vitae jird model [9]. The
L3 and the developing or molting L3 (mL3) have been the focus of
vaccination studies in filarial infections [10–15].
The roles of the different antibody isotype and subclass responses
to O. volvulus crude extract of larval proteins and defined protective
recombinant proteins in onchocerciasis havebeenstudied in greater
detail. Importantly, analysis of the immunoglobulin class and
subclass responses to some of the protective antigens revealed that
these proteins induced mainly cytophilic antibodies, IgG1, IgG3
and/orIgEinPIandINF.Boyerand colleagues[16] showedthatin
areas of high transmission, high IgG3 responses are associated with
protective immunity, a finding which was later confirmed by other
studies [6,17]. In our previous studies we have shown that IgG3 and
IgE responses to crude extracts of L3 as well as the IgG1 and IgG3
responses to a highly abundant larvae-specific protein, Ov-ALT-1,
werealso associatedwith concomitantimmunity[6].ThefilarialOv-
ALT-1 family members have been shown to be protective against
infection with L3 of O. volvulus and in lymphatic filariasis in small
animal models [13,18–20]. Although the precise mechanisms that
mediate killing of O. volvulus L3 in the PI and in individuals who
developed protective immunity with age are still unknown, data
from many studies support the view that antibodies are part of the
effectormechanismsagainstincomingO.volvulus larvalinfectionand
could, together with the Th1 and/or Th2 cytokines produced,
induce efficient anti-L3 antibody-dependent cell mediated cytotox-
icity (ADCC) reactions [6,16,21]. However, no studies were
performed to specifically identify and clone larval proteins that
are possibly associated with the development of concomitant
immunity. In order to identify such proteins, we have screened L3
and mL3 O. volvulus stage-specific cDNA libraries with a pool of sera
from chronically infected patients who have likely developed
concomitant immunity. One of the antigens identified, Ov-CPI-2
(onchocystatin), a previously characterized O. volvulus cysteine
proteinase inhibitor was the most abundant clone recognized by
the immune sera, and was selected for further analysis in two groups
of individuals: the INF and the putatively immune (PI) individuals
[22]. Additionally, we present results on in vitro cytotoxic effects of
human neutrophils on third-stage larvae of Onchocerca volvulus in the
presence of mono-specific antibodies to Ov-CPI-2.
Materials and Methods
Study population and sera
The protocols used in this study were approved by the New York
Blood Center’s IRB and by an NIH accredited Institutional Review
Board of the Medical Research Council Kumba, Cameroon. Each
participant providedinformed consent by signing or thumb printing
a consent form after reading it or after the content of the form was
read and/or explained to them. The serum samples were collected
from residents of 5 villages around Kumba, Cameroon, a
hyperendemic area for onchocerciasis [6]. These villages were
Marumba I, Marumba II, Boa Bakundu, Bombanda, and Bombele.
All participants were born or had resided for more than 10 years in
the villages. The standard skin snip test for detection of microfilariae
(mf) was performed on each subject and clinical symptoms of
onchocerciasis were recorded. The averages of the mf counts of four
skin snips taken from each individual were used in estimating the
individual skin mf densities. None of the subjects had received
ivermectin treatment prior to the collection of blood. In this study
we used 176 serum samples collected from infected individuals; 115
malesand61females,ranging inagefrom3 to75years.Inaddition,
serum samples of 21 putatively immune (PI) subjects were studied.
These individuals had no signsor history of onchocerciasisand were
parasitologicallynegativeduringatleastatwo-yearfollow-upsurvey
employing the standard skin snip test and a polymerase chain
reaction (PCR) assay [6,22].
Immunoscreening of O. volvulus cDNA libraries
In order to identify O. volvulus L3 and mL3 larval proteins that
are recognized by sera from infected individuals who have likely
developed concomitant immunity, l-Unizap XR cDNA expres-
sion libraries of these two life cycle stages (kindly obtained from
Dr. Steven Williams via the NIAID/NIH Filariasis Research
Reagent Repository Center) were immunoscreened as previously
described [12] with only slight modifications. A pool of sera was
prepared using equal volumes of 17 serum samples from infected
individuals, 35 years of age and above, who had previously been
shown to have high anti-L3 and mL3 antibody titres [6]. The
serum pool was first pre-cleared with Escherichia coli lysate (SIGMA,
St Louis, MO) and then used at a final dilution of 1:400 for the
immunoscreening of the cDNA libraries, which were plated at
25,000 plaque-forming units (pfu) per 150 mm diameter plates.
The secondary antibody, goat anti-human IgG conjugated to
horseradish peroxidase (KPL, Gaithersburg, MD) was used at
1:8000 dilution. The positive plaques were identified by incubating
the processed plaque lifts in a solution of phosphate buffered saline
(PBS) containing 0.67 mg/ml diaminobenzidine tetrahydrochlor-
ide (DAB) (SIGMA, St Louis, MO) and 1 ml/ml of 30% H2O2. All
positive plaques were recovered and re-purified using one or two
additional screening cycles. Single phage clones were eventually
recovered and stored in standard phage buffer (SM buffer) in the
presence of 0.3% chloroform.
Author Summary
Onchocerciasis is a chronic and highly debilitating disease
of humans caused by a worm called Onchocerca volvulus.
This worm can live in the human body for over 15 years.
The disease affects mainly the skin and eyes and is the
second leading infectious cause of blindness worldwide.
There is currently no vaccine to prevent the infection.
Available drugs can give short-term relief but cannot cure
the infection. To prevent infection, a vaccine against the
third-stage infective larva, L3, or the developing larva is
required. These stages were shown to be the targets of
protective immunity that develops in individuals who live
in onchocerciasis endemic regions. One type of protective
immunity has been shown to develop with age and is
called concomitant immunity. In the present study, we
have identified a number of larval antigens that may be
associated with the development of such immunity. The
most prominent of these antigens was Ov-CPI-2, also
called onchocystatin, which had previously been shown to
be a promising vaccine candidate. This antigen was further
characterized and confirmed to be possibly also a target of
immune protection that develops in the infected individ-
uals with age and is referred to as concomitant immunity.
Ov-CPI-2 in Protective Immunity
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The inserts of the positive phages were amplified using PCR
with the M13 forward and M13 reverse primers. Briefly, 45 mlo f
PCR supermix (Invitrogen, Carlsbad, USA), 1 ml of each primer
(100 ng/ml) and 1–10 ml of the eluted recombinant phage were
mixed and incubated at 94uC for 5 minutes. Amplification was
carried out for 35 cycles of: denaturation at 94uC for 45 seconds,
annealing at 55uC for 45 seconds, and extension at 72uC for 75
seconds. The final amplification cycle included an additional
extension step at 72uC for 10 minutes (Eppendorf MasterClycler
Gradient, Eppendorf, USA). The PCR amplicons were analyzed
by standard agarose gel electrophoresis on a 1.2% gel. Only clones
that produced a single band on electrophoresis were selected for
sequencing. Those with two or more bands were further plaque
purified before sequencing. The PCR products were purified using
the Rapid PCR Purification System kit (Marligen Biosciences,
Ijamsville, MD) and quantified. Then 10–20 ng of each PCR
product was sequenced using the M13 reverse universal
sequencing primer (GENEWIZ DNA Sequencing Service, New
Jersey, NJ). Gene specific primers were prepared to complete the
sequencing reactions in both directions.
Bioinformatics analyses
BLASTx and BLASTn searches were carried out using the
cDNA sequences in frame with the EcoR1 cloning site at the 59
terminus against the GenBank non-redundant protein and
nucleotide databases, respectively, as well as against the Nembase2
and Wormbase databases. Open reading frames were computed
using the DNASIS software package (Hitachi, CA) or the ORFing
facility at the NCBI homepage (www.ncbi.nlm.nih.gov).
Immune responses to recombinant Ov-CPI-2
Recombinant Ov-CPI-2 fused to Schistosoma japonicum glutathione
S-transferase (GST) polypeptide was expressed in the pGEX-1N
vector and purified as previously described [13]. The IgG1, IgG3,
IgG4 and IgE responses to recombinant GST-Ov-CPI-2 were
determined by indirect ELISA essentially as described by MacDon-
ald et al [6]. Briefly, GST-Ov-CPI-2 or GST were diluted in 0.05M
carbonate-bicarbonate buffer, pH 9.6 at a concentration 1 mg/ml
and used to coat the wells of Immunolon 2 plates (Dynex, VA),
overnight at 4uC. After blocking excess binding sites with 3% (w/v)
casein, individual serum samples which had previously been pre-
cleared with E. coli lysate were diluted to 1:200 and reacted with the
bound antigen for 90 minutes at room temperature. For the analysis
of IgE levels, plates were coated with 10 mg/ml of rOv-CPI-2 or the
control(GST)andserumsampleswerepre-absorbedwithproteinG-
Sepharose (Pharmacia) before being used at a 1:20 dilution. For IgG
subclass responses, the bound antibodies were detected by using a
1:1000 dilution of monoclonal antibodies against different human
IgG subclasses (Hybridoma Reagent Laboratory, Kingsville, Md.).
This step was followed by incubation with a 1:8000 dilution of
horseradish peroxidase-conjugated goat anti-mouse IgG (H+L)
(KPL, Gaithersburg, MD) for another 60 minutes at room
temperature. IgE antibodies in the sera were detected by using a
horseradish peroxidase-conjugated, e-chain-specific anti-human IgE
monoclonal antibody (Zymed, San Francisco, CA) at a dilution of
1:750. Tetramethylbenzidine (SIGMA, St Louis, MO) was prepared
according to the supplier’s recommendations and used as the
enzyme substrate. Absorbance (OD) was read after stopping the
reaction with an equal volume of 1M H2SO4 at 450 nm using an
Emax ELISA reader (Molecular Devices, CA). The OD values for
rOv-CPI-2 are presented as the net values after subtracting the OD
values of the GST control from those of the corresponding GST-Ov-
CPI-2 readings for each serum sample.
In vitro inhibition of L3 molting and killing assays
Monospecific human antibodies to recombinant Ov-CPI-2 were
purified as described by Lustigman et al. [23]. Briefly, cells from
induced lysogenic cultures of lgt11 expressing Ov-CPI-2 were
resuspended in 0.1 M phosphate buffer containing 10 mM
dithiothreitol (DTT) and sonicated. Sodium Dodecyl Sulphate
(SDS) was added to a final concentration of 1% and then
centrifuged at 100006g for 10 min at 4uC. The supernatant was
desalted on a G-25 column using 0.1 M phosphate buffer, 1 mM
DTT, 0.1% SDS, pH 6.8. The supernatants containing b-
galactosidase or b-galactosidase Ov-CPI-2 fusion polypetide were
then coupled to CNBr-Sepharose 4B usingthe protocolprovided by
themanufacturer(Pharmacia). Antibodiesfrom 100 mlofplasmaof
an infected individual, who had high titers of anti-Ov-CPI-2
antibodies, were affinity purified on the immobilized polypeptides.
The mono-specificity of the eluted antibodies was confirmed by
Western blot analysis and immunogold electron microcopy [23].
Negativeantibodieswerepurified fromthesamedonorserafroman
affinity column containing crude extracts of induced lysogenic
culture of lgt11 coupled to the CNBr beads. The IgG titer of the
anti-Ov-CPI-2 purified antibodies was 1:3125 as determined by
ELISA, while the negative antibodies had an anti-Ov-CPI-2 cross
reacting antibody response at 1:5 dilution. The purified antibodies
were passed through a 0.22 mM filter for sterilization.
The L3 killing or inhibition of molting assays were done as
described by Johnson et al. [21]. Briefly, L3 were washed in RPMI-
1640 with 16 GPS (glutamine, penicillin, streptomycin) and the
worms were diluted to 5 worms per 50 mL in the medium
containing 20% fetal calf serum (complete medium). Worms were
distributed to 10 wells of a 96-well plate per treatment group and
2610
5 normal neutrophils isolated by dextran sedimentation were
added to each well in 50 mL of complete medium. Then, 100 mLo f
the anti-Ov-CPI-2 purified antibodies or the negative control
antibodies were added to each of the 10 wells. Complete medium
withoutantibodies wasalsoincludedasa control. The96-well plates
were then incubated at 37uC in a 5% CO2 incubator until day 6
when the cultures were observed for molting; the presence or
absence of the fourth-stage larvae (L4) and the empty cast of the L3
under an inverted microscope. Viability of the larvae was then
determined by MTT (3-(4,5 dimethylthiazol-2yl)-2,5 diphenyl
tetrazolium bromide) staining as previously described [21]. The
experiments were repeated thrice on separate days and the results
presented are the averages and the ranges of the three experiments.
Statistical analysis
The Mann-Whitney test was used to compare the median of
IgG subclass and IgE class responses of the INF and PI groups to
the antigen. Spearman’s rank correlation test was used to test the
significance of the correlation between the antibody responses and
the age of the patients (expressed as the correlation coefficient, r).
Unpaired t test with Welch’s correction was used to compare
mean 6 SEM of % L3 molting and % viability in the presence or
absence of anti-Ov-CPI-2 antibodies and neutrophils. A p value of
,0.05 was considered significant.
Results
Antigenic dominance of Ov-CPI-2 in the L3 and mL3
cDNA libraries
A total of 62 L3 and 25 mL3 immunoreactive cDNA clones out
of a total of 50,000 and 25,000 PFUs, respectively, were isolated
after screening the libraries with a pool of sera from older (.35
years) individuals who were likely to have developed concomitant
immunity. The 87 isolated and sequenced clones were grouped
Ov-CPI-2 in Protective Immunity
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present in both L3 and mL3 (Tables 1 and 2). Interestingly, 12 of
these larval proteins had already been cloned and characterized
using other screening sera and other or similar cDNA libraries.
Many of them (Ov-CPI-2, Ov-RAL-2, Ov-FBA-1, Ov-103 and Ov-
73k) had been shown previously to be potentially associated with
anti-O. volvulus protective immunity [14,24], or to be potential
antigens for the serological diagnosis (Ov-16, OV1CF and Ov-33)
of onchocerciasis (Tables 1 and 2). Moreover, 4 of these (Ov-CPI-2
[13], Ov-FBA-1 [25], Ov-103 [26,27] and Ov-RAL-2 [14,15,2]
have been proven to be protective in O. volvulus mouse model. One
of these, onchocystatin (Ov-CPI-2), a previously characterized
cysteine proteinase inhibitor of O. volvulus was the most abundant
and second most abundant clone recognized by the immune sera
in the L3 (59.7%) and mL3 (16%) cDNA libraries respectively
(Tables 1 and 2). The 4 L3s and 4 mL3s novel proteins identified
accounted for a total of 10.5% and 16% of the isolated L3 and
mL3 clones, respectively. The majority of these O. volvulus novel
proteins have homologues in Brugia malayi. One of the L3 novel
proteins is a putative new member of the fatty acid retinoid
binding protein family (Accession number GQ202199). This
clone, GQ202199, although had only 25% identity to the fatty
acid and retinol binding protein-1 of O. volvulus (ACL98477.1; Ov-
FAR-1), it had 60–62% identity to a B. malayi putative FAR-1
protein [XP001900470. 1]. We have therefore named this protein
Ov-FAR-2. Interestingly, Ov-FAR-1 (also known as Ov-RBP-1 or
Ov20) was shown to be also protective in the O. volvulus mouse
model [14]. Only one encoded protein (Accession number
GQ202201) had no homology to the annotated B. malayi genome
but it had a low level of homology (E value of 3.8; E not
significant!) with a hypothetical C. elegans protein, B0432.14
(NP_001033326.1).
The development of anti-Ov-CPI-2 IgG subclass and IgE
class antibody responses in the infected subjects with
age
Since the recombinant Ov-CPI-2 (rOv-CPI-2) protein was
identified by immunoscreening with sera from infected individuals
35 years of age or more who are likely to have developed
concomitant immunity, it was of interest to investigate the
development of the IgG1, IgG3 and IgE antibody responses to
the antigen in infected individuals in relation to their age (N=176
for IgG1 and IgG3 analyses; N=68 for IgE analysis). Although the
IgG1 responses to rOv-CPI-2 antigen were not correlated with age
(Fig. 1a), they were relatively elevated in all ages; with an overall
82.4% of IgG1 responders (mean 0.6160.72). For the IgG1
analysis, there was no significant difference also in the proportion
of responders vs. the non-responders in individuals of #20 years of
age or those .20 years of age. The IgG3 response to the rOv-CPI-
2 antigen was, however, positively correlated with age (r=0.241;
p,0.01) (Fig. 1b). For the IgE responses there was no significant
correlation with age (Fig. 1c).
Immune responses to rOv-CPI-2 in the putatively
immune individuals vs. the O. volvulus infected subjects
Since the rOv-CPI-2 protein was identified by immunoscreening
with sera from infected individuals who are likely to have
developed concomitant immunity, it was of interest to also
investigate whether the native protein also induced the production
of IgG and IgE antibodies in humans categorized as putatively
immune (PI). These individuals have been exposed to the parasite
over several years but have not developed clinical or parasitolog-
ical signs of infection. The IgG subclass responses to rOv-CPI-2 in
the putatively immune individuals (N=21) were analyzed in
comparison to the responses in age- and sex-matched infected
individuals (N=21). As shown in Figure 2, although the PI and
INF individuals had similar anti-rOv-CPI-2 specific IgG3 responses
(median of 0.3 and 0.32, respectively), the PI individual serum
samples were generally more reactive with the antigen than the
INF individuals (Upper 95% CI value of 0.730 for PI vs. 0.417 for
INF). The median IgG1 responses of the INF, however, were
significantly higher (p=0.03) than those of PI (Fig. 2). The IgG4
responses against rOv-CPI-2 were also significantly higher
(p=0.04) in the INF than in PI as expected since IgG4 antibody
responses are generally associated with an active and patent
infection. On the other hand, the IgE responses between the two
groups were not significantly different.
Cytotoxic effect of anti-Ov-CPI-2 antibodies on L3 larvae
in the presence of normal neutrophils
In vitro cytotoxicity assays demonstrated that purified monospe-
cific human antibodies against rOv-CPI-2 in the presence of
Table 1. cDNA clones isolated from the L3 cDNA library.
SN Name
GenBank
accession
No. of
clones
%i n
screen
%i n
EST
a
1 Onchocystatin precursor (cysteine proteinase inhibitor, OV7, Ov-CPI-2), O. volvulus [13] P22085 37 59.7 1.11
2 Fructose 1,6 bisphosphate aldolase of O. volvulus (Ov-FBA-1) [25] AAD38403 6 9.7 0.12
3 OV-17 antigen precursor (Immunodominant hypodermal antigen), O. volvulus – Ov-RAL-2 [34] P36991 4 6.5 0.17
4 Beta-galactoside-binding lectin, O. volvulus (Ov-GalBP) [35] AAA20541 2 3.2 0.14
5 Microfilariae surface-associated protein, O. volvulus (Ov-103) [26,27] AAA63412 1 1.6 0
6 Gln-rich protein, O. volvulus Ov73k [13] AAC48290 1 1.6 0
7 Cytochrome c oxidase Va polypeptide, with 87% identity to Brugia malayi EDP37396.1; novel and named Ov-COX5a EU807924.1 1 1.6 0
8 New member of the fatty acid retinoid binding protein with 60–61% identity to Brugia malayi XP_001900470.
1; novel and named Ov-FAR-2
GQ202199 2 3.2 0
9 Troponin T, putative, with 88% identity to Brugia malayi XP_001893395.1; novel and named Ov-TNT-2 GQ202200 1 1.6 0
10 Novel protein with 35% identity to Caenorhabditis elegans NP_001033326.1, but no homologue in B. malayi; novel GQ202201 1 1.6 0
a, % abundance of clone in the O. volvulus EST dataset as reported previously [12].
doi:10.1371/journal.pntd.0000800.t001
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from L3 to L4 as determined on day 6 in culture (Table 3), and
resulted in almost a total loss of larval viability (72%). In normal
conditions, about 43–68% of L3s molt to L4 in 6 days. The
differences in % molting between the complete medium control
and the negative non-specific antibodies control were not
statistically different, while they are highly significant when the
effect of monospecific anti-Ov-CPI-2 antibodies on molting was
compared with the two controls (P=0.0007 and P=0.028
respectively). However, the viability of the L3 that did not molt
in the presence of anti-Ov-CPI-2 antibodies was not statistically
different from that of the control cultures. This was mostly due to
the fact that in one of the three experiments the % viability was
82% vs. 0% and 2% in the other two experiments (data not
shown). Longer cultures up to 10 days might be needed for
consistent killing data.
Discussion
The objective of the present study was to identify O. volvulus
larval antigens that may be important in the development of
concomitant immunity to the L3 that develops in the INF with
increasing age, and which is independent of the immune responses
that are directed against the adult worms and microfilariae
associated with patent infection [6]. Concomitant immunity is a
concept initially developed in cancer immunology and later also in
lymphatic filariasis [5,9]. It was only recently reported in
onchocerciasis, where it is believed to contribute in preventing
most of the newly acquired L3 infections from developing, and
results in a stabilization of the adult worm and microfilarial
burdens with age in the INF [3,6,4]. Thus, a pool of sera from
individuals who have likely developed such immunity, based on
their high IgG1 and IgG3 responses to crude extracts of L3 and
mL3, was used to screen the corresponding cDNA libraries. The
20 distinct immunoreactive antigens identified included 4 proteins
(Ov-CPI-2, Ov-FBA-1, Ov-103 and Ov-RAL-2) that had previously
been shown to be protective in a small animal model
[13,25,26,27,14,15,2].
Ov-CPI-2 (O. volvulus cystatin, also known as onchocystatin)
appeared to be, overall, the most immunodominant cDNA clone
reacting with the pool of sera. The high frequency of detection of
the Ov-cpi-2 clone in the present study may be a reflection of its
abundance in the L3 EST datasets as reported previously [12]
and/or of the particular mix of antibodies against the larval
proteins in the pooled sera we used for screening. Due to its
immunodominance, Ov-CPI-2 was selected for further character-
ization with a focus on its increased recognition with age, a
phenomenon that has been previously associated with the
development of concomitant immunity [6] and thus strengthening
its selection as a promising subunit vaccine candidate against O.
volvulus infection. Ov-CPI-2 was previously cloned using antisera
from chimpanzees experimentally immunized with attenuated L3s
[28]. It was shown to be also expressed in all the other stages of the
O. volvulus parasite except in mature microfilariae [28]. It was
localized in the hypodermis, basal layer of the cuticle and in the
eggshell of developing microfilariae [28]. Further studies estab-
lished that this 17 kDa protein could be essential for development
of the infective stage larvae as it probably regulates endogenous
cysteine proteases that are essential for molting [29,30]. Subse-
quent vaccination-challenge experiments in O. volvulus mouse
model using recombinant GST-Ov-CPI-2 and alum as the
adjuvant showed that it could induce significant protection levels
of 43–49% [13]. Further support for its protective role has come
from protective studies done with its homologues in other
nematodes and including lymphatic filariae [31,32,33].
Analysis of the individual levels of the cytophilic antibody IgG3
to Ov-CPI-2 as a function of age showed an age-dependent
association of the antibody responses, which were significantly
increased with age and therefore consistent with the development
of concomitant immunity to larval antigens in this population [6].
The INF and the PI individuals had similar anti-rOv-CPI-2 specific
IgG3 responses (median of 0.3 and 0.32, respectively), while the
Table 2. cDNA clones isolated from the mL3 cDNA library.
SN Name
GenBank
accession
No. of
clones
%i n
screen
%i n
EST
a
1 Ov16, phosphatidylethanolamine binding protein family, O. volvulus [36] P31729 5 20 0
2 Onchocystatin precursor (Cysteine proteinase inhibitor OV7, Ov-CPI-2), O. volvulus [13] P22085 4 16 0
3 Oveg1 (eggshell antigen), O. volvulus [37] AAB35895 3 12 0
4 Ov-17 antigen precursor (Immunodominant hypodermal antigen), O. volvulus-Ov-RAL-2 [34] P36991 2 8 0.17
5 Immunodominant antigen, Ov33-3 precursor P21250 2 8 0
6 Galectin, O. volvulus (Ov87) [38] AAD00843 2 8 0.28
7 Fructose 1,6 bisphosphate aldolase, O. volvulus (Ov-FBA-1) [25] AAD38403 1 4 0.12
8 Thioredoxin peroxidase, O. volvulus (Ov-TPX-2) [39] AAC48312 1 4 0
9 Intermediate filament, O. volvulus (OV1CF) [40] AAA74283 1 4 0
10 Lactate dehydrogenase, putative, with 95% identity to Brugia malayi EDP30958.1; novel and named Ov-LDH-1 GQ202195 1 4 0
11 EF hand family protein, with 98% identity to B. malayi EDP29905.1 and to troponin c in C. elegans; novel and
named Ov-TNC-2
GQ202196 1 4 0
12 Ubiquitin-conjugating enzyme E2-17 kDa, putative with 100% identity to B. malayi EDP37374.1; novel and named
Ov-UBC-2
GQ202197 1 4 0
13 Unknown protein, with 99% identity to hypothetical protein of B. malayi, XP_001894199.1; Also
Caenorhabditis sp. CB5161 28S rRNA gene (92%); novel
GQ202198 1 4 0
a, % abundance of clone in the O. volvulus EST dataset as reported previously [12].
doi:10.1371/journal.pntd.0000800.t002
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or up-regulation of cytophilic (IgG1, IgG3, and IgE) and
complement-fixing (IgG3) antibody responses against larval
antigens, some of which are not necessarily larvae specific, as
was found in this study was shown before to be also associated with
immune protection in onchocerciasis [6,16,17].
Figure 1. The correlation of IgG sub-classes and IgE class responses to rOv-CPI-2 in infected patients with age: Maintenance of high
IgG1 (a) and IgE (c) responses regardless of age; (b) Positive correlation between IgG3 levels and age (r=0.241; P=0.0013).
doi:10.1371/journal.pntd.0000800.g001
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anti-Ov-CPI-2 antibodies may have a role in the ADCC effector
mechanisms. We observed that human neutrophils inhibited
molting of L3 by 79–100% in the presence of purified human
mono-specific antibodies against Ov-CPI-2. Johnson et al [21] have
shown that sera from PI and INF are able to inhibit molting of L3
and kill them when cultured in the presence of neutrophils from
normal humans. Antibodies and ADCC were also found to be an
important part of protective effector mechanisms in O. volvulus
mouse model [15,2].
In one preliminary study, when rOv-CPI-2 was used to stimulate
human peripheral blood mononuclear cells (PBMCs) from INF
individuals (n=6) and PI (n=4), it appeared that it induced a
mixed IFN-c and IL-5 response (cytokine levels were determined
by ELISA) in approximately 50% of the samples (data not shown).
When the cytokine responses were determined using the ELI-
SPOT assay and PBMCs from additional individuals, 6 out of 6 PI
individuals had higher (,106) frequencies of IFN-c than IL-5-
producing cells, while in the INF group 8 out of 10 individuals had
IL-5 dominated responses, and the remaining 2 were only IFN-c
responders. Although the numbers tested so far are small, it points
to the possibility that in the PI, the Th1 cytokine response
dominates, while a more mixed Th1/Th2 response against Ov-
CPI-2 is observed in the INF individuals. Overall, the data
presented in this study clearly support the notion that Ov-CPI-2 is
a promising leading target of protective immunity in onchocerci-
asis and the results discussed justify further vaccination studies on
this antigen for human use.
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